Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Haverford Trust Co

Haverford Trust Co boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 6.5% during the 4th quarter, Holdings Channel reports. The fund owned 344 shares of the biopharmaceutical company’s stock after acquiring an additional 21 shares during the quarter. Haverford Trust Co’s holdings in Regeneron Pharmaceuticals were worth $302,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC raised its holdings in Regeneron Pharmaceuticals by 5.5% in the fourth quarter. Quadrant Capital Group LLC now owns 959 shares of the biopharmaceutical company’s stock valued at $842,000 after acquiring an additional 50 shares in the last quarter. Apexium Financial LP acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $3,540,000. Inceptionr LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $481,000. Vanguard Personalized Indexing Management LLC raised its holdings in Regeneron Pharmaceuticals by 0.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 8,044 shares of the biopharmaceutical company’s stock worth $7,065,000 after purchasing an additional 75 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in Regeneron Pharmaceuticals by 36.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 24,314 shares of the biopharmaceutical company’s stock worth $21,355,000 after purchasing an additional 6,485 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Royal Bank of Canada reissued an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Bank of America raised their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Finally, Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $989.36.

Check Out Our Latest Analysis on REGN

Insider Buying and Selling

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the sale, the executive vice president now owns 37,543 shares of the company’s stock, valued at $36,328,483.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. Insiders have sold 55,925 shares of company stock valued at $54,616,836 over the last quarter. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $982.29 on Friday. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock has a 50 day simple moving average of $942.68 and a 200-day simple moving average of $908.10. The company has a market cap of $108.23 billion, a price-to-earnings ratio of 29.02, a price-to-earnings-growth ratio of 1.99 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.